Acurx Pharmaceuticals LLC


Prices are adjusted according to historical splits.

Acurx Pharmaceuticals LLC Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$43.12 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Acurx Pharmaceuticals LLC had its IPO on 2021-06-25 under the ticker symbol ACXP.

The company operates in the Healthcare sector and Biotechnology industry. Acurx Pharmaceuticals LLC has a staff strength of 4 employees.

Stock update

Shares of Acurx Pharmaceuticals LLC opened at $1.72 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.71 - $1.85, and closed at $1.75.

This is a +1.74% increase from the previous day's closing price.

A total volume of 37,374 shares were traded at the close of the day’s session.

In the last one week, shares of Acurx Pharmaceuticals LLC have slipped by -5.41%.

Acurx Pharmaceuticals LLC's Key Ratios

Acurx Pharmaceuticals LLC has a market cap of $43.12 million, indicating a price to book ratio of 4.3934 and a price to sales ratio of 0.

In the last 12-months Acurx Pharmaceuticals LLC’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Acurx Pharmaceuticals LLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Acurx Pharmaceuticals LLC’s operating margin was 0% while its return on assets stood at -55.23% with a return of equity of -95.34%.

In Q3, Acurx Pharmaceuticals LLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Acurx Pharmaceuticals LLC’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Acurx Pharmaceuticals LLC’s profitability.

Acurx Pharmaceuticals LLC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.5195. Its price to sales ratio in the trailing 12-months stood at 0.

Acurx Pharmaceuticals LLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$10.95 million
Total Liabilities
$1.18 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Acurx Pharmaceuticals LLC ended 2024 with $10.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.95 million while shareholder equity stood at $9.76 million.

Acurx Pharmaceuticals LLC ended 2024 with $0 in deferred long-term liabilities, $1.18 million in other current liabilities, 11593.00 in common stock, $-35380574.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.61 million and cash and short-term investments were $10.61 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Acurx Pharmaceuticals LLC’s total current assets stands at $10.95 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.18 million and inventory worth $0.

In 2024, Acurx Pharmaceuticals LLC's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Acurx Pharmaceuticals LLC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Acurx Pharmaceuticals LLC stock is currently trading at $1.75 per share. It touched a 52-week high of $4.85 and a 52-week low of $4.85. Analysts tracking the stock have a 12-month average target price of $13.33.

Its 50-day moving average was $2 and 200-day moving average was $3.02 The short ratio stood at 1.04 indicating a short percent outstanding of 0%.

Around 2118.1% of the company’s stock are held by insiders while 1176.5% are held by institutions.

Frequently Asked Questions About Acurx Pharmaceuticals LLC

The stock symbol (also called stock or share ticker) of Acurx Pharmaceuticals LLC is ACXP

The IPO of Acurx Pharmaceuticals LLC took place on 2021-06-25

Similar Industry Stocks (Biotechnology)

Last Price
Basanite Inc (BASA)
Modison Ltd-$ (MODISONLTD)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.


259 Liberty Avenue, Staten Island, NY, United States, 10305